Lipoprotein A clinical trials

Explore recruiting lipoprotein a clinical trials.

Recruiting lipoprotein a studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Lipoprotein A trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A multi- center, randomized, double-blind, placebo-controlled parallel–group, dose-finding study to evaluate efficacy, safety, and tolerability of DII235 in adults with elevated Lipoprotein(a)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

J2O-MC-EKBC: KRAKEN: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Once-Daily LY3473329 in Adults with Elevated Lipoprotein(a) at High Risk for Cardiovascular Events

Hungary, Netherlands, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a)

Slovakia, Poland, Greece, Netherlands, Germany, Czechia +16 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase IIb, Multicenter, Randomized, Parallel-group, Double- blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AZD0780 in Participants with Dyslipidemia

Denmark, Czechia, Spain, Slovakia, Hungary

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients with Mixed Dyslipidemia

Sweden, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

J3L-MC-EZEB: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3819469 in Adults with Elevated Lipoprotein(a)

Denmark, Spain, Netherlands, Romania, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Lipoprotein A trials by city

Lipoprotein A in Toronto Lipoprotein A in Vancouver Lipoprotein A in Montreal Lipoprotein A in Calgary Lipoprotein A in Edmonton Lipoprotein A in Ottawa Lipoprotein A in Winnipeg Lipoprotein A in Quebec City Lipoprotein A in Hamilton Lipoprotein A in Kitchener Lipoprotein A in London Lipoprotein A in Halifax Lipoprotein A in New York Lipoprotein A in Los Angeles Lipoprotein A in Chicago Lipoprotein A in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease